VANCOUVER, BC, Feb. 15, 2023 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the “Meeting“), held earlier today. A total of 43,610…


Previous articleIsrael-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US
Next articleAlgernon NeuroScience Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase